International Extranodal Lymphoma Study Group (ielsg)

This phase II trial tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma, a rare blood cancer. The study aims to see how many patients achieve complete remission after one year and how long they stay cancer-free. About 175 par…

This phase 2 trial tests a combination of two drugs, acalabrutinib and tafasitamab, in 26 patients with marginal zone lymphoma that has come back or not responded to previous treatment. The goal is to see how well the combo shrinks or controls the cancer and to check for side eff…

This phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation can control a rare type of lymphoma called NK/T-cell lymphoma. It enrolls 30 patients with early-stage disease who are not healthy enough for standard chemother…

This study tests whether adding zanubrutinib to standard rituximab works better than rituximab alone for people with a rare lymphoma of the spleen (SMZL) who haven't had treatment yet. About 122 participants will receive either the combo or rituximab alone for up to two years, wi…

This study looks at whether people with a type of lymphoma (primary mediastinal large B-cell lymphoma) can safely avoid radiation therapy after standard chemoimmunotherapy if a PET/CT scan shows no active tumor. About 540 patients who had a negative PET/CT after treatment were ra…

This study tests a combination of two drugs, chlorambucil and rituximab, followed by ongoing rituximab maintenance, in 112 people with MALT lymphoma, a slow-growing cancer of the lymph nodes. The goal is to see how many patients achieve complete remission. Participants must have …

This study reviews PET scans from 496 people with marginal zone lymphoma to see how well the scans help with staging and predicting treatment response. Researchers will compare PET results with CT scans and other tests. The goal is to improve how doctors use PET imaging for this …